Copyright
©The Author(s) 2017.
World J Gastroenterol. Aug 7, 2017; 23(29): 5379-5385
Published online Aug 7, 2017. doi: 10.3748/wjg.v23.i29.5379
Published online Aug 7, 2017. doi: 10.3748/wjg.v23.i29.5379
Figure 3 Influence of concomitant furosemide on decreased body weight (%).
Although the difference between each dose category was not significant, high dose of furosemide attenuated the decreased body weight (%) in patients with hepatocellular carcinoma (HCC), while the tendency was opposite in those without HCC.
- Citation: Miyazaki M, Yada M, Tanaka K, Senjyu T, Goya T, Motomura K, Kohjima M, Kato M, Masumoto A, Kotoh K. Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma. World J Gastroenterol 2017; 23(29): 5379-5385
- URL: https://www.wjgnet.com/1007-9327/full/v23/i29/5379.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i29.5379